Vasilis Stavrinides
@vstavrinides
@The_MRC Clinical Research Training Fellow @UCL; @PCFnews Young Investigator; Post-Doctoral Enrichment @turinginst; Graduate Statistician @RoyalStatSoc
ID: 963152678850187267
12-02-2018 20:47:47
86 Tweet
463 Followers
1,1K Following
#AI models developed by King's College London and scaled with #NVIDIACambridge1 can synthesize artificial 3D MRI images of human brains and help scientists understand what a human brain looks like across a variety of ages, genders, and diseases. nvda.ws/3rBkeCs
Congratulations Vasilis Stavrinides on your PhD!!! #celebration #hardwork #AcademicChatter #academia
doi.org/10.1016/j.medi… If we are serious about using ML for some clinical tasks, a lot need to be redefined, e.g. what a good quality image is. Without noise or defect? or "good enough" for NNs to work with? Shaheer U. Saeed has some interesting poitns in his new MedIA paper.
Current Issue: Magnetic Resonance Imaging–guided Active Surveillance of Prostate Cancer: Time to Say Goodbye to Protocol-based Biopsies buff.ly/3Dk68LZ Francesco Giganti Vasilis Stavrinides Caroline Moore #MRI #prostatecancer #biopsies #openscience #openaccess #urology #MedTwitter
The #AUA22 with a European twist 🇬🇧 🇮🇹 🇧🇪 🇵🇱 🇪🇺 Brigham and Women's Hospital Department of Urology UCL Humanitas University Orsi Academy
Excellent European Association of Urology (EAU) session by Antti Rannikko on the future of PSA density kinetics! Our MRI-based AS work on the topic might just be on the right track Francesco Giganti Caroline Moore UCLH UCL Div of Surgery pubmed.ncbi.nlm.nih.gov/33958731/
From Sigrid Carlsson - “if it ain’t broke don’t fix it” genomic testing in AS. RE: genomic differences based on MR-conspicuity: should we be deciding on genomic testing based on MR characteristics & targeting? 1/2 @cooperberg_ucsf Joseph Norris Vasilis Stavrinides Benjamin S. Simpson #EAU22
In our latest Radiology paper we estimate the impact of prostate cancer burden on odds of MRI positivity! Many thanks to co-authors Joseph Norris Francesco Giganti Solon Karapanagiotis UCL Faculty of Life Sciences The Alan Turing Institute Mark Emberton Hashim U. Ahmed pubs.rsna.org/doi/10.1148/ra…
In 161 men from the PROMIS trial, prostate zones that contained Gleason score 3+4 cancer were 3x more likely to be MRI-positive than benign zones and almost 9x if they had a Gleason score ≥4+3. Vasilis Stavrinides Joseph Norris Francesco Giganti Imperial Prostate Medical Research Council bit.ly/3UWgbhr
At BBC for BBC Radio 4 Today interview on how we’re doing better with a safer, more accurate & less harmful pathway MRI, targeted biopsy and focal therapy Imperial Prostate Imperial Urology Surgery and Cancer Imperial College London Imperial NHS 💙 Prostate Cancer UK Time point:2:48. bbc.co.uk/sounds/play/m0…
Our new paper on MRI follow up of targeted biopsy-negative prostate lesions is out! Caroline Moore Francesco Giganti Nora Pashayan Shonit Punwani Mark Emberton Ron Finn UK Research and Innovation The Alan Turing Institute Prostate Cancer Foundation Science and Innovation at Cancer Research UK Eur Urol Focus authors.elsevier.com/sd/article/S24…
Let's kill the real monster...the prostate cancer. #17 at Speed mentoring session at #PCFRetreat23 PCF Science Tyler Seibert MD PhD Renu Eapen Daniel E Spratt Amar Kishan Vasilis Stavrinides #PCSM
